Robert J Soiffer Selected Research

Bronchiolitis Obliterans Syndrome

11/2022	A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
10/2022	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
1/2022	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
1/2022	Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
1/2021	Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease.
1/2020	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease.
10/2019	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
1/2019	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
1/2019	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
11/2018	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert J Soiffer Research Topics

Disease

62	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2022 - 10/2002
42	Neoplasms (Cancer) 01/2022 - 05/2002
37	Bronchiolitis Obliterans Syndrome 11/2022 - 04/2004
30	Leukemia 12/2022 - 10/2002
26	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 09/2003
24	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 09/2003
15	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2022 - 09/2003
10	Infections 01/2022 - 07/2002
10	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2014 - 05/2002
9	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 11/2022 - 07/2010
9	Lymphoma (Lymphomas) 01/2018 - 04/2008
7	Multiple Myeloma 12/2020 - 06/2002
6	Melanoma (Melanoma, Malignant) 11/2005 - 05/2002
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 12/2005
4	B-Cell Lymphoma (Lymphoma, B Cell) 07/2022 - 01/2019
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2019 - 01/2016
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2017 - 04/2008
3	Pathologic Complete Response 09/2012 - 09/2011
3	Iron Overload 06/2012 - 05/2007
2	Injection Site Reaction 12/2022 - 11/2017
2	Bronchiolitis Obliterans 12/2022 - 02/2013
2	Hematuria 11/2022 - 12/2020
2	Hypotension (Low Blood Pressure) 11/2022 - 03/2016
2	Cytokine Release Syndrome 01/2022 - 01/2021
2	Diarrhea 01/2021 - 09/2011
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 01/2019
2	Disease Progression 01/2019 - 01/2015
2	Opportunistic Infections (Opportunistic Infection) 01/2019 - 01/2018
2	Inflammation (Inflammations) 01/2018 - 01/2015
2	Carcinoma (Carcinomatosis) 01/2018 - 04/2003
2	Hodgkin Disease (Hodgkin's Disease) 05/2017 - 02/2009
2	Venous Thromboembolism 01/2017 - 02/2013
2	Myeloid Leukemia (Leukemia, Myelocytic) 03/2015 - 02/2010
2	Pneumonia (Pneumonitis) 06/2014 - 05/2004
2	Exanthema (Rash) 02/2014 - 03/2011
2	Colitis 08/2013 - 09/2011

Drug/Important Bio-Agent (IBA)

18	Tacrolimus (Prograf)FDA LinkGeneric 12/2022 - 09/2003
16	AntigensIBA 01/2018 - 05/2002
14	Sirolimus (Rapamycin)FDA Link 01/2020 - 09/2003
13	Interleukin-2 (IL2)IBA 11/2022 - 09/2006
12	Methotrexate (Mexate)FDA LinkGeneric 12/2022 - 09/2003
11	VaccinesIBA 12/2022 - 05/2002
10	AntibodiesIBA 12/2017 - 05/2002
8	SteroidsIBA 11/2022 - 08/2004
7	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 05/2002
7	Busulfan (Busulfex)FDA Link 01/2020 - 04/2008
6	defibrotideIBA 01/2020 - 07/2010
6	fludarabineIBA 01/2020 - 04/2008
6	Minor Histocompatibility AntigensIBA 03/2010 - 01/2003
5	CytokinesIBA 01/2022 - 11/2002
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 09/2003
5	Pharmaceutical PreparationsIBA 12/2020 - 02/2013
5	Bortezomib (Velcade)FDA Link 01/2018 - 10/2009
5	Monoclonal AntibodiesIBA 01/2017 - 10/2002
5	Complementary DNA (cDNA)IBA 03/2015 - 05/2002
4	Calcineurin InhibitorsIBA 01/2022 - 05/2004
4	trans-crotonin (CTN)IBA 01/2022 - 05/2012
4	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2021 - 09/2004
4	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 06/2013
4	Proteins (Proteins, Gene)FDA Link 07/2016 - 03/2003
3	IpilimumabIBA 10/2021 - 02/2009
3	Immune Checkpoint InhibitorsIBA 01/2019 - 07/2016
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 10/2016
3	Thomsen-Friedenreich antibodiesIBA 11/2018 - 06/2011
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 06/2012
3	DNA (Deoxyribonucleic Acid)IBA 12/2016 - 11/2012
3	Immunoglobulins (Immunoglobulin)IBA 06/2014 - 02/2010
3	B-Cell Activating FactorIBA 05/2014 - 10/2007
3	Rituximab (Mabthera)FDA Link 06/2013 - 04/2010
3	Peptides (Polypeptides)IBA 03/2012 - 03/2003
2	Alemtuzumab (Campath)FDA Link 04/2022 - 05/2013
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2019
2	Natalizumab (Tysabri)FDA Link 05/2021 - 01/2021
2	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 10/2016
2	Phosphotransferases (Kinase)IBA 01/2020 - 12/2008
2	GlobulinsIBA 11/2018 - 12/2017
2	Biological ProductsIBA 11/2017 - 04/2003
2	Ferritins (Ferritin)IBA 06/2012 - 06/2011
2	IronIBA 06/2012 - 06/2011
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2009 - 12/2003
2	AutoantibodiesIBA 03/2007 - 10/2002
2	EpitopesIBA 03/2007 - 11/2005
2	Immunoglobulin G (IgG)IBA 06/2005 - 03/2003
2	Polysaccharides (Glycans)IBA 03/2005 - 02/2003
2	Imatinib Mesylate (Gleevec)FDA Link 08/2004 - 11/2003

Therapy/Procedure

69	Hematopoietic Stem Cell Transplantation 11/2022 - 07/2002
42	Therapeutics 11/2022 - 06/2002
37	Transplantation 10/2021 - 06/2002
29	Stem Cell Transplantation 01/2021 - 12/2003
27	Cell Transplantation 10/2022 - 02/2003
11	Homologous Transplantation 04/2022 - 08/2004
11	Drug Therapy (Chemotherapy) 01/2021 - 06/2002
6	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 04/2016 - 05/2004
3	Immunotherapy 01/2022 - 10/2002
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 06/2005 - 07/2002
2	Aftercare (After-Treatment) 11/2021 - 02/2010
2	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2021 - 01/2021
2	Platelet Transfusion (Blood Platelet Transfusions) 01/2020 - 01/2019
2	Salvage Therapy 12/2019 - 04/2010
2	Autologous Transplantation 05/2017 - 02/2007